SCHEMBL4549875

SCHEMBL4549875

CC(C)(C)OC(=O)NC1(c2ccc(B3OC(C)(C)C(C)(C)O3)cc2F)CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.44
BACE2 Q9Y5Z0 1/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
AAK1 Q2M2I8 2/20 0.42
ROCK1 Q13464 1/20 0.39
USP30 Q70CQ3 1/20 0.37
HIF1A Q16665 3/20 0.35
DGAT1 O75907 1/20 0.34
PDE2A O00408 2/20 0.33
RORC P51449 1/20 0.33
F2 P00734 1/20 0.33
F11 P03951 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
AKT1 P31749 1/20 0.32
AKT2 P31751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17645835 0.96 BACE1 (0.46) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL2699886 0.85 ROCK1 (0.43) BACE1BACE2ROCK1HIF1ADGAT1
SCHEMBL361565 0.82 AAK1 (0.47) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL1142034 0.80 AAK1 (0.47) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL17645721 0.80 ROCK1 (0.44) BACE1BACE2ROCK1HIF1ADGAT1
SCHEMBL4549947 0.78 AAK1 (0.49) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL2147588 0.77 ROCK1 (0.43) ROCK1DGAT1RORCLIPG
SCHEMBL65795 0.77 AAK1 (0.49) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL2036558 0.76 PRMT5 (0.43) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL31388805 0.76 USP30 (0.43) BACE1BACE2PRMT5WDR77AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569331-B2 Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds ARQULE, INC. (US) 2013-10-29 US disclosed
US-8569331-B2 Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds ARQULE, INC. (US) 2013-10-29 US disclosed
WO-2012061342-A2 SUBSTITUTED BENZO-IMIDAZO-PYRIDO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2012-05-10 WO disclosed
US-20120108574-A1 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds ARQULE, INC. (US) 2012-05-03 US disclosed
US-20120108574-A1 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds ARQULE, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108574-A1 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds BRD4, BRPF3, BRD3 BACE1 1049/4885BACE2 1880/4885PRMT5 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.